Glooko Expands into Inpatient Diabetes Care with Acquisition of Monarch Medical Technologies

Glooko, a leader in outpatient diabetes management platforms, has announced its acquisition of Monarch Medical Technologies, marking a significant expansion into the inpatient diabetes care market. The move brings Monarch's FDA-cleared EndoTool software under Glooko's umbrella, positioning the company to offer comprehensive diabetes management solutions across the entire care continuum.

Strategic Expansion into Hospital Settings

Glooko's acquisition of Monarch Medical Technologies represents a strategic shift for the company, which has primarily focused on outpatient diabetes management. The integration of EndoTool, Monarch's flagship product for managing insulin doses in hospital settings, allows Glooko to address the critical need for effective glycemic control in hospitalized patients.

Mike Alvarez, CEO of Glooko, emphasized the importance of this acquisition, stating, "This acquisition represents a pivotal step in Glooko's mission to transform diabetes management in every care setting." He further explained that the move positions Glooko to "deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety."

EndoTool: Enhancing Inpatient Insulin Management

EndoTool, first FDA-cleared in 2006, is designed to assist clinicians in calculating insulin doses for hospitalized patients in real-time. The software integrates with electronic health records and employs a personalized algorithm that accounts for broader organ function, continuously monitoring patient responses and providing alerts to care team members.

This technology addresses a significant need in hospital care, as an estimated 30% to 40% of hospitalized patients require some form of insulin therapy. Effective glycemic management in these settings is crucial not only for maintaining glucose levels but also for avoiding serious complications during other treatments.

Bridging the Gap Between Hospital and Home Care

The acquisition positions Glooko to create a seamless transition for diabetes patients moving from hospital care to outpatient management. Dr. Mark Clements, Glooko's Chief Medical and Strategy Officer, highlighted the importance of this continuity, stating, "Effective glycemic management doesn't begin or end at the hospital doors. It's a continuous journey."

By integrating EndoTool with its existing outpatient platform, Glooko aims to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the care continuum.

Glooko's existing technology, used by over 8,000 clinics worldwide, can aggregate data from more than 200 devices, including blood glucose meters, insulin pumps, and wearable continuous glucose monitors. The addition of EndoTool expands this capability to include acute hospital care and remote patient monitoring through the discharge process.